GeoInvesting is now following Electromed Inc. (AMEX:ELMD) as shares have more than doubled on the heels of strong Q2 2016 EPS and Revenues that easily exceeded analysts estimates.
It’s Time to Look Carefully at Electromed Inc.
Long time GeoInvesting members already know that we like stories like that of Electromed that capitalize on the favorable growth prospects of the home health care industry. This is what prompted us to publish our article on REPRO MED (OOTC:REPR) on October 7, 2014. The majority of REPR’s revenues and growth come from its FDA-regulated “FREEDOM60” mechanical infusion pump system, as well as related needle sets used to deliver medication to primary immune deficiency patients. REPR is primarily targeted to the outpatient/home care market.
Subscribe to Read Our Full Analysis on Electromed
If you are interested in hearing more on our opinion on whether ELMD business momentum can continue please you can Opt- in here.
Alternatively, to read our full original analysis now, you can subscribe to our premium service by clicking here.